1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Global Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027

Global Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027

  • October 2021
  • 288 pages
  • ID: 6188482
  • Format: PDF
  • KBV Research

Summary

Table of Contents

The Global Inflammatory Bowel Disease Treatment Market size is expected to reach $29.2 billion by 2027, rising at a market growth of 8.1% CAGR during the forecast period. Inflammatory bowel disease refers to a group of intestinal disorders that leads to chronic inflammations like swelling and pain in the intestines. Few of the known inflammatory bowel disease are Ulcerative colitis and Crohn’s disease. The effect of both types of inflammatory bowel disease is witnessed on the digestive system. There are various treatments available that only help to slow down the progress of the disease. The kind of treatment required for inflammatory bowel disease largely depends upon symptoms and the type of IBD. Moreover, the prescribed medicines assist patients in controlling inflammation.

The key factor contributing to the growth of the market is the growing prevalence of ulcerative disease and Crohn’s disease around the world. Additionally, the presence of strong pipeline drugs like risankizumab, ustekinumab, tofacitinib, & upadacitinib, and the growing adoption of biologics for the inflammatory bowel disease treatment are projected to accelerate the growth of the market in the upcoming period. However, the outbreak of the COVID-19 has an adverse effect on the growth of the market as a rapid decrease was observed in the diagnosis of inflammatory bowel disease, owing to the imposition of lockdown in several countries around the world.

COVID-19 Impact

The outbreak of the COVID-19 pandemic had a negative impact across the world. During the Quarter 2 of 2020, there was a rapid increase witnessed in the number of COVID-19 patients due to which, WHO declared it as a Public Health Emergency. Governments across the world formed rules to reduce the impact of the COVID-19. Lockdown was imposed that led to the shutdown of businesses, which had a negative impact on the economies of nations. Traveling was banned that disrupted the supply chains. People were forced to stay at their homes and maintain social distance.

Market Growth Factors:

High government spending on IBD treatment research

As the prevalence of inflammatory bowel disease is increasing rapidly, governments across several nations are focusing on finding efficient and less painful treatments for IBD patients. Thus, governments are highly investing in research and development activities to develop new products that will provide relief to patients suffering from inflammatory bowel disease. Moreover, the government is also providing reimbursement policies to patients due to which, a large number of patients are adopting IBD treatment.

Rapid urbanization led to an unhealthy lifestyle

As the world is evolving, most of the nations are shifting towards urbanization. People residing in different nations are largely following modern culture and trending activities. People are also inclining towards a luxurious life, which has given rise to an unhealthy lifestyle. In addition, the advent of advanced technologies has made people lazy and inactive. Additionally, people are adopting unhealthy activities such as smoking and consuming alcohol. The unhealthy lifestyle has resulted in giving rise to various health-related problems like inflammatory bowel disease.

Market Restraining Factor:

Strict regulatory policies for IBD drugs

The guidelines for the British Society of Gastroenterology were developed on the management of inflammatory bowel disease in youngsters. The major UK authorities of Ulcerative colitis and Crohn’s disease healthcare were involved in the development of guidelines. These guidelines were imposed at the time of rapid change in several factors of inflammatory bowel disease. The imposition of stringent guidelines has created barriers to the growth of the inflammatory bowel disease treatment market.

Type Outlook

Based on Type, the market is segmented into Crohn’s Disease and Ulcerative Colitis. In 2020, the Crohn’s Disease segment acquired the largest revenue share of the inflammatory bowel disease treatment market and would continue the progress during the forecast period. The major factors accelerating the growth of the segment are the growing rate of biologics prescription and the high prevalence rate.

Distribution Channel Outlook

Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. In 2020, the hospital pharmacy segment collected the maximum revenue share of the inflammatory bowel disease treatment market and is expected to display similar kind of trend even during the forecast years. The factors contributing to the growth of the segment are rapidly growing hospitalization of inflammatory bowel disease patients and higher cost of biologics.

Route of Administration Outlook

Based on Route of Administration, the market is segmented into Injectable and Oral. The oral segment is anticipated to display a prominent CAGR during the forecasting years. Factors such as the presence of robust oral pipeline products to treat patients suffering from inflammatory bowel disease and the approval of JAK inhibitors for inflammatory bowel disease treatment are responsible for the growth of this segment. Moreover, the forthcoming launch of S1P modulators and JAK inhibitors will propel the growth of the market over the forecast period.

Drug Class Outlook

Based on Drug Class, the market is segmented into TNF inhibitors, Anti-integrin, IL inhibitors, Corticosteroids, JAK inhibitors, Aminosalicylates and Others. The drug segment like aminosalicylates, corticosteroids, and anti-integrin are displaying a prominent share in the inflammatory bowel disease treatment market. Aminosalicylates refer to the first-line therapy for inflammatory bowel disease treatment. JAK inhibitors segment would showcase the fastest growth rate during the forecasting years.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. Asia-Pacific would exhibit the fastest CAGR of inflammatory bowel disease treatment during the forecasting years. The growth of the regional market would be driven by the increasing novel drug approval, the growing prevalence of ulcerative colitis and Crohn’s disease across the region, and increasing prescription of biosimilars. Based on a study by NCBI, in comparison to women, the chances of Crohn’s disease are higher in men.

The major strategies followed by the market participants are Approvals. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc., Amgen, Inc., Novartis AG, and Johnson & Johnson are the forerunners in the Inflammatory Bowel Disease Treatment Market. Companies such as Takeda Pharmaceutical Company Limited, UCB S.A., Allergan PLC are some of the key innovators in the market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (AbbVie), Johnson & Johnson, Merck Group, Amgen, Inc., Eli Lilly and Company, Biogen, Inc., Pfizer, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, and UCB S.A.

Recent Strategies Deployed in Inflammatory Bowel Disease Treatment Market

Partnerships, Collaborations, and Agreements:

Jul-2021: Merck collaborated with B Braun, a German medical and pharmaceutical device company. Together, the companies aimed to treat inflammatory diseases utilizing neurostimulator devices. Moreover, the companies would allow multi-channel selective stimulation, could solve the important challenges, and provide neurostimulator treatment to patients that are suffering from chronic inflammatory diseases.

Sep-2020: Merck teamed up with Seattle Genetics, an American biotechnology company. Together, the companies would introduce two new strategic oncology collaborations. These two strategic collaborations would allow Seattle Genetics to further expand Merck’s broad oncology offerings and pipeline, and to continue Seattle Genetics efforts to enhance and extend the lives of various patients suffering from cancer.

Jul-2020: UCB signed an agreement with Ferring Pharmaceuticals, a Swiss multinational biopharmaceutical company. Under this agreement, the companies aimed to commercialize the prefilled syringe formulation of CIMZIA across the United States, particularly for the treatment of Crohn’s disease.

Acquisitions and Mergers:

Apr-2021: Merck took over Pandion Therapeutics, a clinical-stage biotechnology company. This acquisition would cater all the requirements of patients living with autoimmune diseases.

Mar-2021: Amgen signed an agreement to acquire Rodeo, a privately held biopharmaceutical company. Under this acquisition, the company would design first-in-class therapeutics for patients.

Feb-2020: Takeda took over PvP Biologics, a biotechnology company. Under this acquisition, the company would use TAK-062 for the treatment of uncontrolled celiac disease.

Geographical Expansions:

May-2021: Amgen expanded its geographical reach in Canada by introducing AMGEVITA for the treatment of 11 chronic inflammatory conditions. Through this expansion, the company aimed to use AMGEVITA to expand the number of treatment options available for Canadians suffering from chronic inflammatory diseases.

Approvals and Trials:

Sep-2021: Takeda Pharmaceutical Company received approval to manufacture and market Alofisel development code Cx601 from the Japan Ministry of Health, Labour and Welfare. The company would use this development code for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease.

Aug-2021: Novartis received approval for Cosentyx from the China National Medical Products Administration. Through this approval, the company aimed to use Cosentyx for the treatment of moderate-to-severe plaque psoriasis in pediatric patients who are candidates for systemic therapy or phototherapy.

Aug-2021: UCB received approval for BIMZELX from the European Commission. The company would use BIMZELX for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Aug-2021: AbbVie received approval for RINVOQ from the European Commission. The company aimed to use RINVOQ for the treatment of moderate to severe atopic dermatitis across adults and adolescents of 12 years and above, who are candidates for systemic therapy.

Jun-2021: Novartis got approval for Cosentyx from the U.S. Food and Drug Administration. The company would use Cosentyx for the treatment of moderate to severe plaque psoriasis in pediatric patients, for six years and older who are candidates for phototherapy1 or systemic therapy.

May-2021: Janssen, a subsidiary of Johnson & Johnson got approval for PONVORY from the European Commission. The company would use PONVORY for the treatment of adult patients with relapsing multiple sclerosis with active disease defined by imaging or clinical features.

Mar-2021: Janssen, a subsidiary of Johnson & Johnson received approval for PONVORY from the U.S. Food and Drug Administration. The company would use PONVORY to treat adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease, active secondary progressive disease, and clinically isolated syndrome.

Feb-2021: Pfizer received the approval of supplemental Biologics License Application for PANZYGA from the U.S. Food and Drug Administration. PANZYGA would treat adult patients with a rare neurological disease of the peripheral nerves known as chronic inflammatory demyelinating polyneuropathy.

Feb-2021: AbbVie got approval for HUMIRA from the U.S. Food and Drug Administration. The company would use HUMIRA for the treatment of moderately to severely active ulcerative colitis in pediatric patients of 5 years and above.

Aug-2020: Novartis received approval for Kesimpta from the US Food and Drug Administration. Under this approval, the company aimed to use Kesimpta for the treatment of relapsing forms of multiple sclerosis, including relapsing-remitting disease, active secondary progressive disease, and clinically isolated syndrome, in adults.

Mar-2020: Takeda Pharmaceutical Company got approval for Entyvio from the China National Medical Products Administration. The company aimed to use Entyvio for the treatment of adult patients with moderate to severe active ulcerative colitis or Crohn’s disease, who have had a poor response with, lost response to, or were intolerant to conventional therapies or tumor necrosis factor-alpha (TNF?) inhibitors.

Scope of the Study

Market Segments covered in the Report:

By Type

• Crohn’s Disease and

• Ulcerative Colitis

By Distribution Channel

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

By Route of Administration

• Injectable

• Oral

By Drug Class

• TNF inhibitors

• Anti-integrin

• IL inhibitors

• Corticosteroids

• JAK inhibitors

• Aminosalicylates

• Others

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

• LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Allergan PLC (AbbVie)

• Johnson & Johnson

• Merck Group

• Amgen, Inc.

• Eli Lilly and Company

• Biogen, Inc.

• Pfizer, Inc.

• Novartis AG

• Takeda Pharmaceutical Company Limited

• UCB S.A.

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Ceramide Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

  • $ 2499
  • January 2022
  • 143 pages

The global ceramide market reached a value of US$ 348.8 Million in 2021. Looking forward, the analyst expects the market to reach US$ 503.3 Million by 2027, exhibiting a CAGR of 5.70% during 2022-2027. ...

  • World
  • Diabetes
  • Pharmaceutical
  • Industry analysis

ref:plp2021

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on